Abstract
The last years have shown enormous advancement in the therapeutic potential of RNA-related treatments, specifically for antisense oligonucleotide (ASO)-based drugs, leading to increased numbers of ASO regulatory approvals. In this study we focus on SPL84, an inhaled ASO-based drug, developed for the treatment of the pulmonary disease, Cystic Fibrosis (CF). Pulmonary drug delivery is challenging, due to a variety of biological, physical, chemical, and structural barriers, especially when aiming to target the cell nucleus. The efficient distribution of SPL84 in the lungs, penetration into the cells and nucleus, and stability are critical parameters that will impact drug efficacy in a clinical setting. In this study, we demonstrate the proper distribution and cell and nucleus penetration of SPL84 in mouse and monkey lungs. In vivo and in vitro studies confirmed the stability and mobility of our inhaled ASO drug through CF patient-derived mucus and in lung lysosomal extracts. Our results, supported by a promising pre-clinical pharmacological effect, emphasize the high potential of SPL84 as an effective drug for the treatment of CF patients.
In addition, successfully tackling the lung distribution of SPL84 and specific cell targeting offers huge opportunities for further development of SpliSense inhaled ASO-based drugs for unmet pulmonary diseases.
Competing Interest Statement
E.O, L.F, O.A, C.S, Y.O, and G.H are Splisense employees. B.K is the CSO of Splisense. This research is supported by Splisense LTD and by a Cystic Fibrosis Foundation TDA.
Funding Statement
This research is supported by Splisense LTD and by a Cystic Fibrosis Foundation TDA.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Sputum samples were provided by the UNC Adult Pulmonary Clinic and collected under UNC IRB, # 15-2431. Mucus samples harvested from UNC cell cultures are acquired from the UNC Marsico Lung Institute Tissue Procurement and Cell Culture Core under UNC IRB protocol # 03-1396
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
